<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618316</url>
  </required_header>
  <id_info>
    <org_study_id>PXL008-023</org_study_id>
    <nct_id>NCT03618316</nct_id>
  </id_info>
  <brief_title>Effect of Cimetidine on the PK of Imeglimin</brief_title>
  <official_title>An Open-label, One-sequence Study to Assess the Effect of Repeated Oral Doses of Cimetidine on the Single Dose Pharmacokinetics, Safety and Tolerability of Imeglimin in Healthy Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is an open-label assessment of the interaction of imeglimin with cimetidine. Up to
      16 healthy men and women will receive a single oral dose of 1,500 mg imeglimin alone followed
      by a second dose of imeglimin during repeated doses of 400 mg cimetidine taken twice daily
      for 6 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of imeglimin</measure>
    <time_frame>At Day 1</time_frame>
    <description>Cmax: peak plasma concentration after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of imeglimin</measure>
    <time_frame>From day 1 to day 3</time_frame>
    <description>AUC last:area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>from day 1 to day 17</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Open-label imeglimin + cimetidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin</intervention_name>
    <description>2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)</description>
    <arm_group_label>Open-label imeglimin + cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine</intervention_name>
    <description>400 mg of cimetidine bid from Day 5 to Day 10</description>
    <arm_group_label>Open-label imeglimin + cimetidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI : 18.5-29.9

          -  Body weight â‰¥ 60 kg

          -  willing to use reliable contraception

          -  able to give fully informed written consent.

        Exclusion Criteria:

          -  Pregnant or lactating woman, or sexually active woman of child-bearing potential not
             using reliable contraception

          -  Clinically relevant abnormal findings at the screening assessment

          -  Clinically significant vital signs outside the acceptable range at screening

          -  Clinically relevant abnormal medical history, surgery or concurrent medical condition

          -  Acute or chronic illness

          -  Estimated glomerular filtration rate less than 80 mL/min/1.73 m2

          -  Severe adverse reaction to any drug or sensitivity to the trial medication or its
             components

          -  Significant food allergy; vegetarian or vegan

          -  Participation in other clinical trials of unlicensed or prescription medicines, or
             loss of more than 400 mL blood, within the 3 months before first dose of trial
             medication

          -  Drug or alcohol abuse

          -  Smoking of more than 5 cigarettes daily

          -  Possibility that subject will not cooperate

          -  Positive test for hepatitis B &amp; C, HIV

          -  Objection by a General Practitioner
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Caucasian</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

